Skip to main
FBLG

Fibrobiologics Inc (FBLG) Stock Forecast & Price Target

Fibrobiologics Inc (FBLG) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

FibroBiologics Inc. has demonstrated substantial progress in its clinical-stage pipeline, with increased research and development expenses reflecting a commitment to advancing its fibroblast-based therapies for chronic diseases. The company’s promising findings, including significant biomarker improvements from its lead product candidate CYWC628, indicate its potential to enhance tissue regeneration while mitigating inflammation, thereby addressing pressing medical needs. Furthermore, strengthening its capital structure through direct offerings and eliminating outstanding debt has positioned FibroBiologics favorably to pursue future financing opportunities as it prepares for clinical initiation and seeks to validate its therapeutic approach.

Bears say

FibroBiologics Inc. faces a negative outlook primarily due to the announcement of a 1-for-20 reverse stock split, which tends to disrupt existing shareholder bases and may lead to selling pressure and reduced trading liquidity as investors adjust their positions. This action, typically viewed as a sign of financial distress, may result in prolonged pressure on investor sentiment and hinder the company's ability to attract new investment, thereby constraining valuation expansion despite any potential progress in its biotechnology initiatives. Furthermore, while there is a significant market opportunity in the burn care sector, the overall investor confidence has been damaged, suggesting that it may take several quarters for the company to recover from the negative impact of this corporate action.

Fibrobiologics Inc (FBLG) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fibrobiologics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fibrobiologics Inc (FBLG) Forecast

Analysts have given Fibrobiologics Inc (FBLG) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Fibrobiologics Inc (FBLG) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fibrobiologics Inc (FBLG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.